Aktienanalyse wird geladen …
DHR · NYSE · Diagnostics & Research · USA
224,49 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 24,57 Mrd. | 3,61 Mrd. | 5,05 $ | 716,1 Mio. | 1,3 Mio · 0,2 % | 22,4 Mio · 3,1 % | 59,1 % | 14,7 % | 7,35 $ | 0,42 $ | — |
| 2024 | 23,88 Mrd. | 3,9 Mrd. | 5,29 $ | 737,2 Mio. | 1,3 Mio · 0,2 % | 7,2 Mio · 1 % | 59,5 % | 16,3 % | 7,18 $ | 0,39 $ | — |
| 2023 | 23,89 Mrd. | 4,76 Mrd. | 6,38 $ | 743,1 Mio. | 1,4 Mio · 0,2 % | — | 58,7 % | 19,9 % | 7,78 $ | 0,41 $ | — |
| 2022 | 26,64 Mrd. | 7,21 Mrd. | 9,66 $ | 737,1 Mio. | 1,3 Mio · 0,2 % | 1 Mio · 0,1 % | 60,8 % | 27,1 % | 10,04 $ | 0,40 $ | — |
| 2021 | 24,8 Mrd. | 6,43 Mrd. | 8,61 $ | 736,8 Mio. | 0,8 Mio · 0,1 % | — | 61,4 % | 25,9 % | 9,66 $ | 0,25 $ | — |
| 2020 | 22,28 Mrd. | 3,65 Mrd. | 4,89 $ | 718,7 Mio. | 0,8 Mio · 0,1 % | 7,6 Mio · 1,1 % | 56 % | 16,4 % | 7,54 $ | 0,26 $ | — |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Bruttomarge | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 6,27 Mrd. | 870 Mio. | 1,23 $ | 707,6 Mio. | 57,6 % | 13,9 % | 1,79 $ |
| Q1 2026 | 5,95 Mrd. | 1,03 Mrd. | 1,45 $ | 711,2 Mio. | 60,3 % | 17,3 % | 1,53 $ |
| Q4 2025 | 6,84 Mrd. | 1,2 Mrd. | 1,68 $ | 711 Mio. | 58 % | 17,5 % | 2,44 $ |
| Q3 2025 | 6,05 Mrd. | 908 Mio. | 1,27 $ | 713,7 Mio. | 58,2 % | 15 % | 1,92 $ |
| Q2 2025 | 5,94 Mrd. | 555 Mio. | 0,77 $ | 719,1 Mio. | 59,4 % | 9,4 % | 1,52 $ |
| Q1 2025 | 5,74 Mrd. | 954 Mio. | 1,32 $ | 720,8 Mio. | 61,2 % | 16,6 % | 1,46 $ |
| Q4 2024 | 6,54 Mrd. | 1,09 Mrd. | 1,52 $ | — | 59,5 % | 16,6 % | 2,10 $ |
| Q3 2024 | 5,8 Mrd. | 818 Mio. | 1,12 $ | 729,4 Mio. | 58,7 % | 14,1 % | 1,67 $ |
TDM Reagent Kit Market Forecasts Growth from $2.87B (2026) to $6.96B by 2032, Profiling Abbott, Roche, Danaher, Siemens Healthineers & Thermo Fisher
Danaher (DHR) Stock Looks Reasonable On Label Free Detection Growth
Global Pharmaceutical Filtration Report: Biologics Manufacturing Shifts as Danaher, Merck KGaA, Sartorius, 3M and Thermo Fisher Reshape the Market
Bioreactors Market Outlook 2026-2035 - Featuring Profiles of 3 Leading Companies: Sartorius, Thermo Fisher Scientific, and Danaher
Danaher Schedules Third Quarter 2026 Earnings Conference Call
Capitalize on the Label-Free Detection Market Shift: Track How Danaher, Sartorius, Agilent, Bruker and Revvity Are Disrupting R&D ROI and Reshaping Global Revenue Through 2030
Danaher Corp. is a global science and technology company focused on biotechnology, life sciences, and diagnostics. The company develops and supplies mission-critical tools, consumables, instruments, software, and services used in research, bioprocessing, clinical testing, and laboratory workflows. Its current business is organized around Biotechnology, Life Sciences, and Diagnostics, with offerings that support areas such as biologics manufacturing, molecular and clinical diagnostics, genomics, and analytical instrumentation. Danaher serves customers across healthcare, research, and industrial settings, helping laboratories and life sciences organizations improve efficiency, precision, and productivity. Headquartered in Washington, D.C., Danaher operates through a portfolio of specialized operating companies that provide products and solutions for scientific discovery, disease detection, and the production of biologic therapies.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest DHR und jede andere Aktie unbegrenzt.